Sisram Medical Bundle
What is the history of Sisram Medical?
Sisram Medical, a global leader in energy-based medical aesthetic solutions, was established in 2013. This pivotal moment followed Fosun Pharma's acquisition of Alma Lasers, a prominent name in energy-based medical aesthetics devices.
Incorporated in Israel, the company initially aimed to build a comprehensive wellness ecosystem, extending beyond medical-grade solutions to improve consumers' daily lives.
Today, Sisram Medical is a distinguished global consumer wellness group with a presence in over 100 countries. The company is a significant player in the medical aesthetic device market, which was valued at US$26.15 billion in 2024 and is projected to reach US$29.16 billion in 2025. This growth highlights the company's evolution and its position in an expanding industry, offering solutions like those detailed in a Sisram Medical PESTEL Analysis.
What is the Sisram Medical Founding Story?
Sisram Medical Ltd was formally incorporated in Israel on April 25, 2013. Its establishment was a direct result of Fosun Pharma's strategic acquisition of a 95.20% equity interest in Alma Lasers for US$221.63 million on May 27, 2013. This acquisition marked the beginning of Sisram Medical's journey, with Mr. Guo Guangchang of Fosun International Holdings Limited as its ultimate controlling shareholder.
Sisram Medical Origins and Early Strategy
The founding of Sisram Medical was driven by the ambition to solidify and expand its leadership in the energy-based medical aesthetics market. The company's initial vision was to leverage Alma Lasers' established expertise and product portfolio, including well-known systems like Soprano, Harmony, and Accent.
- Formal incorporation date: April 25, 2013, in Israel.
- Acquisition by Fosun Pharma: 95.20% equity in Alma Lasers for US$221.63 million on May 27, 2013.
- Ultimate controlling shareholder: Mr. Guo Guangchang, associated with Fosun International Holdings Limited.
- Initial business focus: Design, development, manufacture, and sale of energy-based aesthetic medical and minimally invasive treatment systems.
- Early funding sources: Fosun Pharma and its affiliates, including Ample Up, CML, and Pramerica-Fosun Fund.
- Strategic goal: To create an integrated consumer-focused ecosystem and expand into adjacent wellness domains.
- The Competitors Landscape of Sisram Medical provides further context on its market positioning.
Sisram Medical SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Sisram Medical?
Since its establishment in 2013, the company experienced significant early growth, building on existing foundations. A major step in its development was its listing on the Hong Kong Stock Exchange in September 2017, marking it as the first Israeli company to achieve this on the Main Board.
Public Offering and Global Visibility
The company's 2017 listing on the Hong Kong Stock Exchange provided a crucial platform for raising capital and enhancing its international profile. This milestone was instrumental in its subsequent expansion efforts.
Expanding Direct Sales Channels
In its early years, the company prioritized establishing direct sales offices to better serve its global customer base. This strategy saw new offices opened in the United Kingdom in 2022, followed by Dubai in early 2023, and Thailand in September 2024.
Strategic Acquisition in China
A significant strategic move was the acquisition of a 60% stake in a key Chinese distributor in July 2023 for approximately US$40 million. This acquisition allowed for a transition to direct operations in mainland China, bolstering market penetration.
Portfolio Diversification and Financial Performance
The company expanded its product offerings to include injectables and cosmeceuticals, enriching its wellness ecosystem. This strategic shift contributed to direct sales accounting for 87% of total revenue in 2024, with a gross profit margin of 62.1% in the same year.
Sisram Medical PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Sisram Medical history?
Sisram Medical has navigated a path marked by significant advancements and strategic expansions, alongside facing considerable market headwinds. The company's journey reflects a commitment to innovation and market penetration, as detailed in its Target Market of Sisram Medical profile.
| Year | Milestone |
|---|---|
| 2024 | Achieved record-breaking performance in the U.S. with the Alma Harmony™ platform in the first half of the year. |
| 2024 | Secured NMPA approval for DAXXIFY® in mainland China in September. |
| 2024 | Received medical device approval for Profhilo® in Hainan, China, in April. |
| 2024 | Launched Revanesse® dermal fillers in the UK. |
| 2025 | Scheduled for global launch of Alma IQ™, an intelligent skin analysis and consultation solution. |
| 2025 | Planned launch of DAXXIFY® in mainland China. |
| First Half 2025 | Anticipated launch of skincare solutions. |
Sisram Medical has introduced several key innovations, including the Alma Harmony™, an advanced multi-modal anti-aging platform, and Alma IQ™, an intelligent skin analysis and consultation solution. The company also expanded its injectables portfolio with the NMPA approval for DAXXIFY® and the launch of Revanesse® dermal fillers.
Alma Harmony™ Launch
This advanced multi-modal anti-aging platform demonstrated record-breaking performance in the U.S. during the first half of 2024, leading to a highly demanded global rollout.
Alma IQ™ Introduction
An intelligent skin analysis and consultation solution, Alma IQ™ saw immediate adoption in the North American market and is slated for a global launch in 2025.
DAXXIFY® China Approval
The company secured NMPA approval for DAXXIFY®, a significant botulinum toxin product, in mainland China in September 2024, with a planned launch in 2025.
Profhilo® Hainan Approval
Medical device approval for Profhilo® was obtained in Hainan, China, in April 2024, further expanding the company's presence in the region.
Revanesse® UK Launch
The company successfully launched its Revanesse® dermal fillers in the United Kingdom market.
Skincare Solutions
The company is set to launch new skincare solutions in the first half of 2025, diversifying its product ecosystem.
Sisram Medical faced financial challenges in 2024, with a 2.8% decrease in overall revenue to US$349.1 million and a 12.6% drop in net profit to US$28.8 million. These declines were largely due to a 12.4% reduction in North American revenue, influenced by a high-interest rate environment, and macroeconomic pressures in Europe during the first half of 2023.
Revenue Decline
In 2024, the company experienced a 2.8% decrease in overall revenue, reaching US$349.1 million, and a 12.6% fall in net profit to US$28.8 million.
North American Market Impact
A challenging high-interest rate environment led to a 12.4% decline in North American revenue, significantly impacting overall financial performance.
Sales Model Transition
The transition to a direct sales model in key markets resulted in a temporary reallocation of resources, which affected short-term revenue figures.
European Market Conditions
The macroeconomic environment in the first half of 2023 presented challenges in the European market, contributing to the company's overall performance.
Regulatory Compliance
Successfully achieving compliance with European MDR requirements for its quality management system is a crucial step for future European product launches.
Adaptive Strategies
The company is actively accelerating digital transformation, launching new direct sales offices, and diversifying its product range to overcome market pressures and maintain its industry position.
Sisram Medical Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Sisram Medical?
The journey of Sisram Medical began with its incorporation in Israel on April 25, 2013, following Fosun Pharma's acquisition of Alma Lasers. The company later debuted on the Hong Kong Stock Exchange on September 19, 2017. Sisram Medical history showcases a consistent growth trajectory, marked by strategic expansions and product launches.
| Year | Key Event |
|---|---|
| 2013 | Sisram Medical Ltd is incorporated in Israel; Fosun Pharma acquires 95.20% of Alma Lasers. |
| 2017 | Sisram Medical lists on the Main Board of the Hong Kong Stock Exchange (HKEX: 1696.HK). |
| 2020 | Initiates digital transformation and records a 26.0% revenue increase in H2 over H1 despite COVID-19. |
| 2022 | Establishes a new direct sales office in the United Kingdom. |
| 2023 | Establishes a direct sales subsidiary in Dubai and launches its first Sisram Wellness Center in Chicago. Completes acquisition of 60% stake in PhotonMed International. |
| 2024 | Profhilo® receives medical device approval in Hainan; Alma Harmony™ achieves record U.S. performance and global launch. DAXXIFY® receives NMPA approval for mainland China; direct sales office established in Thailand. |
| 2024 (Fiscal Year End) | Reports US$349.1 million in revenue and US$28.8 million in net profit. |
| 2025 (H1) | Anticipated global launch of Alma IQ™ and new skincare solutions. |
| 2025 (June 24) | Scheduled Annual General Meeting. |
| 2025 (September 9) | Payment date for the final dividend of HK$0.126 per share. |
Strategic Market Focus and Expansion
Sisram Medical is prioritizing growth in North America and Asia-Pacific. The company is also expanding its global direct sales presence to reach more customers.
Accelerating Injectable Offerings
The company plans to speed up the commercialization of its injectable products, including DAXXIFY® in China. Key fillers like Profhilo®, Hallura®, and Revanesse® will also be promoted across various markets.
Innovative Skincare and Market Growth
A significant focus is on developing an innovative skincare concept, with a highly anticipated launch in the first half of 2025. This aligns with the broader medical aesthetic devices market, projected to grow substantially.
Vision for an Integrated Wellness Ecosystem
Sisram Medical's strategic initiatives are driven by its founding vision of an integrated wellness ecosystem. The company aims to adapt to market needs and leverage technology to enhance global quality of life, building on its Brief History of Sisram Medical.
Sisram Medical Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Sisram Medical Company?
- What is Growth Strategy and Future Prospects of Sisram Medical Company?
- How Does Sisram Medical Company Work?
- What is Sales and Marketing Strategy of Sisram Medical Company?
- What are Mission Vision & Core Values of Sisram Medical Company?
- Who Owns Sisram Medical Company?
- What is Customer Demographics and Target Market of Sisram Medical Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.